Corgi Genomics & Precision Medicine ETF (GNMX) closed at $37.39 on November 3, 2026, up 1.8% from the previous close, on volume of 668 shares (30-day average 3,074).
Data as of November 3, 2026.
No headlines found.
No press releases found.
No news found.
The Fund is an exchange-traded fund ("ETF") that seeks to meet its objective by having Corgi Strategies, LLC (the "Adviser") actively manage the Fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions (patient stratification), targeted therapies, and data-driven healthcare. For purposes of this policy, the Fund considers the following activities: gene sequencing and analysis, bioinformatics and computational biology, molecular diagnostics and companion tests, gene editing and gene therapy platforms, targeted biologics and small molecule therapeutics, laboratory tools and reagents, clinical data platforms, and enabling services that support the discovery, development, and delivery of personalized medicine across prevention, diagnosis, and treatment.
Corgi Genomics & Precision Medicine ETF trades on the BATS stock market under the symbol GNMX.
As of November 4, 2026, GNMX stock price climbed to $38.26 with 802 million shares trading.
GNMX has a market cap of $1.34 million. This is considered a Sub-Micro Cap stock.
GNMX support price is $36.35 and resistance is $38.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNMX shares will trade within this expected range on the day.
